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Abstract
Purpose of review—The diagnosis of primary ciliary dyskinesia (PCD) has relied on analysis
of ciliary motility and ultrastructure; however, these tests are not readily available and have not
been standardized. Consequently, the diagnosis of PCD may be delayed or missed or made
incorrectly. This review outlines the potential utility of new diagnostic tests, including
measurement of nasal nitric oxide (NO) production and systematic analysis for mutations in gene
encoding ciliary proteins.
Recent findings—Clinical manifestations of PCD have been expanded to include neonatal
respiratory distress and heterotaxy. Measurement of nasal NO has emerged as a useful screening
test for PCD based on the very low levels in PCD (approximately 1/10 of normal values). Genetic
testing is emerging for PCD and demonstrates extensive genetic heterogeneity. Some genes and
gene mutations involved in PCD have been defined. Approximately one third of PCD cases have
identifiable gene mutations in one of 6 different genes. An international effort is focused on
defining PCD-causing defects in other genes.
Summary—The incorporation of nasal NO measurement as a screening test to define probable
PCD cases and gene mutation analysis to make a definitive diagnosis of PCD should enhance
diagnostic evaluation of PCD.
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Introduction
Over the past 2 years, there has been increased interest in the biology of cilia and diseases
associated with defects in cilia (ciliopathies) [1*, 2*, 3**], including primary ciliary
dyskinesia (PCD). PCD is a rare, inherited, usually autosomal recessive, disorder with
impaired ciliary function leading to progressive sino-pulmonary disease [4*].
Approximately half of PCD patients have situs inversus totalis, reflecting dysmotility of
embryonic nodal cilia. Male infertility is common reflecting sperm tail dysmotility.
Diagnosis of PCD has relied on identification of ciliary dysmotility and specific ciliary
ultrastructural defects in outer dynein arms, inner dynein arms or central apparatus. Because
these tests are not readily available or standardized, the diagnosis is often delayed or missed
or made incorrectly.
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Clinical manifestations in PCD
Upper and lower respiratory tract manifestations are cardinal features of PCD [5, 6, 7, 8] and
often are present in first month of life; however, the diagnosis is delayed because features
overlap with other pediatric disorders [6]. Upper respiratory tract features include chronic
year-round, nasal drainage that begins in the first weeks of life, chronic sinusitis that
becomes apparent once the sinuses have developed and chronic otitis media that is most
prevalent in the first years of life and often managed with tympanostomy tube placement [5,
6, 7, 8]. Lower respiratory features include neonatal respiratory distress, chronic productive
cough, chronic bronchitis, recurrent pneumonia and bronchiectasis. Most patients have a
history of neonatal respiratory distress with tachypnea, hypoxia and, occasionally,
respiratory failure requiring mechanical ventilation that has been attributed to transient
tachypnea of the newborn or neonatal pneumonia [7, 9,10]. Chronic, year-round productive
cough [5, 7, 8, 9] often begins in the first weeks of life, but is attributed to recurrent viral
infections, reflux and aspiration or cough-variant asthma. Chronic bronchitis and recurrent
pneumonia with radiographic features of air-trapping and atelectasis are common in
childhood and lead to bronchiectasis that typically involving the middle and lower lobes and
may occur in childhood [11*, 12*, 13*] and even in the first years of life [14*].
Laterality defects occur in approximately half of PCD patients [5, 7]. Indeed, the first
reported cases in the early 1900's had situs inversus totalis (mirror image orientation of
thoraco-abdominal organs), chronic sinusitis and bronchiectasis, known as the Kartagener
triad. A recent study showed that heterotaxy (situs ambiguous or laterality defect other than
situs inversus totalis) occurs with a prevalence of at least 6% and can be associated with
complex congenital heart disease in PCD [15**]. In addition, a mouse model study [16**]
demonstrated that complex congenital heart disease was caused by mutations in one of the
dynein genes (DNAH5) that accounts for over 20% of PCD cases (see PCD gene mutation
analysis section below). These studies suggest that PCD-associated ciliary defects that affect
embryonic nodal cilia can cause not only situs inversus totalis, but also heterotaxy and
complex congenital heart disease [17*]; therefore, infants with congenital heart disease and
respiratory symptoms should be evaluated for PCD.
A variety of other features may be seen in PCD. Almost all men with PCD have infertility
from impaired sperm motility. Hydrocephalus occurs rarely in PCD, although a frequent
feature in mouse models of PCD, suggesting that ependymal ciliary dysmotility has greater
implications in mice. Retinitis pigmentosa, polycystic kidney disease, liver cysts and biliary
atresia (all features of ciliopathies of sensory cilia) have been reported rarely in PCD [5]
suggesting that there may be overlap of diseases associated with defects in motile and
sensory cilia.
DIAGNOSTIC TESTS
The specialized techniques required for PCD diagnostic tests are not standardized or readily
available; therefore, referral to research centers or tertiary diagnostic centers may be needed
[18*].
Ciliary ultrastructure
The cornerstone diagnostic test for PCD has been examination of ciliary ultrastructure by
transmission electron microscopy. Each normal cilium contains an array of longitudinal
microtubules, consisting of nine doublets arranged in an outer circle around a central pair (9
plus 2 pattern). Dynein arms are large protein complexes (including 2-3 heavy chains, 2-4
intermediate chains, and at least 8 light chains) that are attached to the nine microtubule
doublets as distinct inner and outer “arms” that are discernable on electron micrographs of
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ciliary cross-sections [1] (see Figure 1). Dyneins generate the force for ciliary movement
through microtubule sliding. The 9 plus 2 array of microtubules is maintained by inter-
tubular linkages and accessory proteins (discernable on electron micrographs as radial
spokes and nexin links) [1]. Several ciliary ultrastructural defects have been described, but
the most frequent are absence or shortening of outer dynein arms or inner dynein arms,
absence of radial spokes or loss of central pair of microtubules with transposition of a
peripheral doublet to the center [5, 7]. A recent study demonstrated a genetic diagnosis
involving one of the dynein proteins (DNAH11), but normal ciliary ultrastructure and a
subtle alteration in ciliary beat detectable by high-speed videomicroscopy [19**],
demonstrating that ultrastructural analysis alone will not identify all PCD cases. Absence of
cilia, or acilia syndrome, has been described in a few families [20].
Ciliary motility
In the past, light microscopic examination of ciliary beat was used as a screening test for
PCD. While this approach may identify immotile or markedly dyskinetic cilia, ciliary beat
may appear normal in some cases of PCD. Digital high-speed videomicroscopy has been
used to detect more subtle abnormalities in ciliary beat pattern and has demonstrated that
certain ciliary beat patterns are associated with specific ultrastructural defects - immotile or
limited flickering for outer dynein arm defects; low amplitude stiff beat for isolated inner
dynein arm defect of radial spoke defect; circular, whip-like beat for central microtubular
defects such as transposition [21]. This specialized technique has been incorporated into the
PCD evaluation at some PCD diagnostic centers [18].
Nasal nitric oxide
Several studies have demonstrated that nasal NO is extremely low (10-15% of normal) in
PCD patients suggesting that nasal NO measurement may be a useful screening test for PCD
[7, 22, 23, 24]. Because low nasal NO levels have been reported in a limited number of other
disorders with overlapping clinical features (e.g., cystic fibrosis [7, 23, 25], panbronchiolitis
[26], and nasal polyposis [27]), confirmatory ciliary ultrastructure analysis and/or genetic
mutation analysis are needed for a firm PCD diagnosis. At present, no FDA-approved
devices for measurement of nasal NO are available. Nasal nitric measurement is used
predominantly in research studies in the United States, but has become part of the diagnostic
clinical testing at centers in Europe [19]. Nasal NO is measured by a non-invasive approach
in which nasal air, aspirated through a catheter inserted at opening of one nostril, is directed
to an NO analyzer that typically uses ozone-/NO2-based chemiluminescence for direct on-
line measurement of NO [28]. The nasal catheter is inserted through a foam sleeve or olive
that is wedged at the opening of the nostril to limit dilution of nasal NO by ambient air.
During the measurement, the subject is asked to perform maneuvers to close the soft palate
to limit contamination with gases exhaled from the lung because exhaled NO from lower
airways is typically much lower than nasal NO. These techniques have been used
reproducibly in children over 5 years of age, but often are not possible in younger children
who cannot cooperate with palate closure maneuvers. Measured NO concentration in parts
per billion (PPB) varies with flow rate through the sampling line; however, nasal NO output
(the product of transnasal flow rate and measured NO concentration) expressed in nL/min is
constant over a wide range of transnasal flow rates and is the preferred nomenclature for
reporting nasal NO measurements [28]. Cut-off values to delineate PCD from normal
subjects range from 50-100 nl/min depending on the specific technique used [7, 22, 23, 24].
Recent studies have focused on optimizing and standardizing techniques for measuring nasal
NO especially in children under 5 years of age who are unable to cooperate with maneuvers
to close the soft palate [29*, 30*, 31*, 32*, 33*]. The biologic role of nasal NO has not been
defined; however, its postulated function is local host defense through its antimicrobial
actions and regulation of ciliary motility [34, 35].
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PCD gene mutation analysis
Genetic diagnosis of PCD is challenging due to the extensive genetic heterogeneity and the
large size of the disease-causing genes. To date, 6 genes have been linked with PCD (Figure
1). Two dynein genes, encoding ODA intermediate chain (DNAI1) and heavy chain
(DNAH5) have been seen to be mutated in ~30-38% of the families evaluated [36, 37, 38,
39, 40, 41, 42]. Despite allelic heterogeneity, presence of founder mutations and mutation
clusters led to the development of the clinical molecular genetic test for PCD, which aids in
the diagnosis in a subset of PCD patients with the ODA defects. Mutations in other ODA
genes (TXNDC3 and DNAI2) have been noted in a small fraction (~2%) of all PCD patients
[43, 44*], and have not been included in the clinical genetic panel yet. Recently, mutations
have been described in ktu in ~12% of PCD patients with defects in both the ODA and IDA
[45**]. The ktu encodes a cytoplasmic protein, Ktu/PF13, that is required for the dynein
complex assembly. Although, allelic heterogeneity was present, given the relatively small
size of this gene (3 exons), it is conceivable to incorporate this gene into the clinical genetic
panel, especially for the subset of PCD families that have ultrastructural defects in both
ODA and IDA. Diagnosis of PCD is very difficult in patients who present with the
compatible clinical phenotype, but normal ultrastructure findings. Very recently, DNAH11
was conclusively shown to be mutated in a PCD family [19]. At this juncture, studies to
define large scale mutation profiling in a variety of PCD patients are needed to delineate the
exact burden of DNAH11 in the causation of PCD.
Genetic tests are very reliable because the presence of biallelic mutations in trans are
diagnostic and the mutation identification techniques are more highly standardized and
easier to perform, compared to ciliary ultrastructural analysis. Our knowledge about the
PCD disease-causing genes is still emerging in parallel with the technology development to
handle mutation scanning for multiple large genes. For most recent information on PCD
genetic tests, refer to http://www.genetests.org/ which is updated as new mutations are
identified.
Other diagnostic tests
Mucociliary clearance measurement (a non-invasive assessment of ciliary function in the
lower airways) is available at a limited number of PCD diagnostic centers and has been
proposed as an adjunctive diagnostic test for PCD [46*].
DIAGNOSTIC APPROACH
The criteria for the diagnosis of PCD include presence of characteristic phenotypic features
and supporting laboratory studies. Only a few phenotypic features are apparent at birth (e.g.,
neonatal respiratory distress, laterality defects), but some phenotypic features become more
obvious over the first years of life (e.g., chronic sinusitis, recurrent respiratory infections)
and others may not be apparent until adulthood (e.g., male infertility). Therefore, the
minimum number of phenotypic features varies with age from at least 3 in early childhood
to typically 5 or more in late childhood and adulthood. The diagnostic approach to PCD
(outlined in Table 1) is subject to modification with further development and refinement of
diagnostic tests for PCD, as well as better definition of phenotypic features. The availability
of genetic testing has enhanced our ability to make a definitive diagnosis of PCD, even in
individuals with normal ciliary ultrastructure [19**]. Further studies are needed to provide
more extensive genetic testing as well as to standardize other diagnostic testing. In the
meantime, careful distinction between a definitive diagnosis of PCD versus a probable or
possible PCD diagnosis is important for clinical decision-making as well as for research
studies. Criteria for a definitive diagnosis of PCD are presence of at 3 (typically 5 or more)
phenotypic features and either a genetic diagnosis (identification of 2 disease causing
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mutations) or identification of ciliary ultrastructural defects that are specific for PCD (with
no overlap with secondary ciliary defects that occur following airway infections or exposure
to airway irritants). Individuals who have ultrastructural defects that may also be seen in
secondary ciliary dyskinesia warrant repeat biopsy to determine if the defect resolves as
expected after recovery from an airway insult; however, persistence of the defect does not
exclude a secondary dyskinesia from an chronic airway insult.
As reviewed above, nasal NO measurement is a useful screening test for PCD. In an
individual with at least 3 phenotypic features of PCD and a very low nasal NO level, PCD is
highly probable, particularly if diagnostic tests for cystic fibrosis are negative. Only highly
specialized research centers have expertise with the other adjunctive tests (high-speed
videomicroscopy and mucociliary clearance measurement) to define criteria that distinguish
“probable” versus “possible” PCD. With further research and standardization, these tests
may become more useful as diagnostic tests.
CONCLUSIONS
The diagnosis of PCD is evolving with better definition of phenotypic features and
expansion of diagnostic tests. Nasal nitric oxide measurement is likely to become a useful
screening test for PCD once it is standardized and available in the clinical setting.
Identification of genes involved in PCD is a very active area of research. Presently, available
genetic testing for PCD can identify approximately one-third of individuals with PCD. The
other adjunctive tests for PCD require specialized equipment and expertise and are likely to
be restricted to PCD research centers.
Acknowledgments
M.A.Z and M.R.K. are supported by National Institutes of Health (NIH) grant R01 HL071798. M.W.L., M.A.Z.
and M.R.K. are supported by NIH grant U54 RR019480 (PI: M.R. Knowles) that funds a large multi-center
consortium, the “Genetic Disorders of Mucociliary Clearance Consortium” that is part of the Rare Disease Clinical
Research Network (url: http://rarediseasesnetwork.epi.usf.edu/gdmcc/index.htm). In addition to the authors, other
Site PIs and Project PIs involve in primary ciliary research through this consortium are: Dr. Kenneth Olivier
(National Institute of Allergy and Infectious Diseases, Bethesda, MD), Drs. Thomas Ferkol and Jeffrey Atkinson
(Washington University in St. Louis, Mo), Dr. Scott Sagel (The Children's Hospital Colorado, Denver, CO), Drs.
Margaret Rosenfeld and Moira Aitken (Children's Hospital and Regional Medical Center, Seattle, WA), Dr. Carlos
Milla (Stanford University Medical Center, Palo Alto, CA), Dr. Stephanie Davis (The University of North Carolina
at Chapel Hill, NC), and Dr. Sharon Dell (The Hospital for Sick Children, Toronto, Ontario, Canada).
Disclosure of Funding: National Institutes of Health grants U54RR019480 and R01 HL071798
References and recommended reading
Papers of particular interest, published within the annual period of review, have been
highlighted as:
* of special interest
** of outstanding interest
1*. Satir P, Christensen ST. Structure and function of mammalian cilia. Histochem Cell Biol. 2008;
129:687–93. [PubMed: 18365235] This article provides comprehensive review of cilia biology.
2*. Marshall WF. The cell biological basis of ciliary disease. J Cell Biol. 2008; 180:17–21. [PubMed:
18180369] This article provides overview of the complexity of ciliopathies.
3**. Fliegauf M, Benzing T, Omran H. When cilia go bad: cilia defects and ciliopathies. Nat Rev Mol
Cell Biol. 2007; 8:880–93. [PubMed: 17955020] This excellent, comprehensive review article
provides a detailed discussion of cilia (defining types of cilia and their functions), and then
Leigh et al. Page 5













addresses the wide range of diseases associated with ciliopathies, including primary ciliary
dyskinesia.
4*. Bush A, Chodhari R, Collins N, et al. Primary ciliary dyskinesia: current state of the art. Arch Dis
Child. 2007; 92:1136–40. [PubMed: 17634184] * This article outlines the key clinical features
that distinguish PCD and approach to diagnosis.
5. Bush A, Cole P, Hariri M, MacKay I, et al. Primary ciliary dyskinesia: diagnosis and standards of
care. Eur Respir J. 1998; 12:982–988. [PubMed: 9817179]
6. Coren ME, Meeks M, Morrison I, et al. Primary ciliary dyskinesia: age at diagnosis and symptom
history. Acta Paediatr. 2002; 91:667–669. [PubMed: 12162599]
7. Noone PG, Leigh MW, Sannuti A, et al. Primary ciliary dyskinesia: Diagnostic and phenotypic
features. Am J Respir Crit Care Med. 2004; 169:459–467. [PubMed: 14656747]
8. Leigh, MW. Primary ciliary dyskinesia. In: Chernick, V.; Boat, TF.; Wilmott, RW.; Bush, A.,
editors. Kendig's Disorders of the Respiratory Tract in Children. 7th edition. Saunders-Elsevier;
Philadelphia: 2006. p. 485-490.
9. Hossain T, Kappelman MD, Perez-Atayde AR, Young GJ, et al. Primary ciliary dyskinesia as a
cause of neonatal respiratory distress: implications for the neonatologist. J Perinatol. 2003; 23:684–
687. [PubMed: 14647169]
10. Ferkol T, Leigh M. Primary ciliary dyskinesia and newborn respiratory distress. Semin Perinatol.
2006; 30:335–40. [PubMed: 17142159]
11*. Jain K, Padley SP, Goldtraw EJ, et al. Primary ciliary dyskinesia in the paediatric population:
range and severity of radiological findings in a cohort of patients receiving tertiary care. Clin
Radiol. 2007; 62:986–93. [PubMed: 17765464] This is one of 3 recent articles defining
radiographic features in PCD and focuses on the pediatric age group.
12*. Kennedy MP, Noone PG, Leigh MW, et al. High-resolution CT of patients with primary ciliary
dyskinesia. AJR Am J Roentgenol. 2007; 188:1232–8. [PubMed: 17449765] This is one of 3
recent articles defining radiographic features in PCD and spans the age range from 1-73 years.
13*. Santamaria F, Montella S, Tiddens HA, et al. Structural and functional lung disease in primary
ciliary dyskinesia. Chest. 2008; 134:351–7. [PubMed: 18403663] This is one of 3 recent articles
defining radiographic features in PCD and includes a comparison of severity of changes in PCD
with age-matched CF patients.
14*. Brown DE, Pittman JE, Leigh MW, et al. Early lung disease in young children with primary
ciliary dyskinesia. Pediatr Pulmonol. 2008; 43:514–6. [PubMed: 18383332] This manuscript
describes structural and functional changes in early PCD lung disease in 3 young children (less
than 4 years of age).
15**. Kennedy MP, Omran H, Leigh MW, et al. Congenital heart disease and other heterotaxic defects
in a large cohort of patients with primary ciliary dyskinesia. Circulation. 2007; 115:2814–21.
[PubMed: 17515466] This international, multi-center, retrospective study is the first large study
to demonstrate that heterotaxy and complex congenital heart disease are associated with PCD.
16**. Tan SY, Rosenthal J, Zhao XQ, et al. Heterotaxy and complex structural heart defects in a
mutant mouse model of primary ciliary dyskinesia. J Clin Invest. 2007; 117:3742–52. [PubMed:
18037990] This study demonstrates that heterotaxy and complex congenital heart defects result
from mutation in DNAH5, one of the PCD genes, in a mutant mouse model.
17*. Brueckner M. Heterotaxia, congenital heart disease, and primary ciliary dyskinesia. Circulation.
2007; 115:2793–5. [PubMed: 17548739] This editorial to the article by Kennedy et al [15**]
discusses the potential role of cilia defects in heterotaxy and congenital heart disease
18*. O'Callaghan C, Chilvers M, Hogg C, et al. Diagnosing primary ciliary dyskinesia. Thorax. 2007;
62:656–7. [PubMed: 17687094] This article describes the role of specialized PCD diagnostic
centers in the United Kingdom.
19**. Schwabe GC, Hoffmann K, Loges NT, et al. Primary ciliary dyskinesia associated with normal
axoneme ultrastructure is caused by DNAH11 mutations. Hum Mutat. 2008; 29:289–98.
[PubMed: 18022865] This study is the first to demonstrate definitively that PCD occurs in
individuals with normal ciliary ultrastructure through a genetic diagnosis (mutations in one of the
outer dynein arm genes, DNAH11).
Leigh et al. Page 6













20. Wessels MW, Avital A, Failly M, et al. Candidate gene analysis in three families with acilia
syndrome. Am J Med Genet. 2008; 146A:1765–7. [PubMed: 18512228]
21. Chilvers MA, Rutman A, O'Callaghan C. Ciliary beat pattern is associated with specific
ultrastructural defects in primary ciliary dyskinesia. J Allergy Clin Immunol. 2003; 112:518–24.
[PubMed: 13679810]
22. Narang I, Ersu R, Wilson NM, Bush A. Nitric oxide in chronic airway inflammation in children:
diagnostic use and pathophysiological significance. Thorax. 2002; 57:586–9. [PubMed: 12096200]
23. Wodehouse T, Kharitonov SA, Mackay IS, Barnes PJ, et al. Nasal nitric oxide measurements for
the screening of primary ciliary dyskinesia. Eur Respir J. 2003; 21:43–47. [PubMed: 12570107]
24. Corbelli R, Bringolf-Isler B, Amacher A, et al. Nasal nitric oxide measurements to screen children
for primary ciliary dyskinesia. Chest. 2004; 126:1054–9. [PubMed: 15486363]
25. Balfour-Lynn IM, Laverty A, Dinwiddie R. Reduced upper airway nitric oxide in cystic fibrosis.
Arch Dis Child. 1996; 75:319–322. [PubMed: 8984918]
26. Nakano H, Ide H, Imada M, et al. Reduced nasal nitric oxide in diffuse panbronchiolitis. Am J
Respir Crit Care Med. 2000; 162:2218–2220. [PubMed: 11112141]
27. Colantonio D, Brouillette L, Parikh A, Scadding GK. Paradoxical low nasal nitric oxide in nasal
polyposis. Clin Exp Allergy. 2002; 32:698–701. [PubMed: 11994092]
28. ATS/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement
of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005. Am J Respir Crit Care
Med. 2005; 171:912–930. [PubMed: 15817806]
29*. Santamaria F, De Stefano S, Montella S, et al. Nasal nitric oxide assessment in primary ciliary
dyskinesia using aspiration, exhalation, and humming. Med Sci Monit. 2008; 14:CR80–85.
[PubMed: 18227765] This study compares effectiveness of maneuvers that may improve
performance of nasal NO measurement.
30*. Piacentini GL, Bodini A, Peroni D, et al. Nasal nitric oxide for early diagnosis of primary ciliary
dyskinesia: practical issues in children. Respir Med. 2008; 102:541–7. [PubMed: 18187313] This
article reviews techniques and challenges of measuring nasal NO in children.
31*. Corbelli R, Hammer J. Measurement of nasal nitric oxide. Paediatr Respir Rev. 2007; 8:269–72.
[PubMed: 17868927] This article reviews techniques and challenges of measuring nasal NO in
children.
32*. de Winter-de Groot KM, van der Ent CK. Measurement of nasal nitric oxide: evaluation of six
different sampling methods. Eur J Clin Invest. 2009; 39:72–7. [PubMed: 19087132] This study
compares effectiveness of maneuvers that may improve performance of nasal NO measurement.
33*. Gupta R, Gupta N, Turner SW. A methodology for measurements of nasal nitric oxide in children
under 5 yr. Pediatr Allergy Immunol. 2008; 19:233–8. [PubMed: 18397407] This study evaluates
techniques for measuring nasal NO in children less than 5 years of age.
34. Jain B, Rubinstein I, Robbins RA, et al. Modulation of airway epithelial cell ciliary beat frequency
by nitric oxide. Biochem Biophys Res Commun. 1993; 191:83–8. [PubMed: 7680560]
35. Stout SL, Wyatt TA, Adams JJ, Sisson JH. Nitric oxide-dependent cilia regulatory enzyme
localization in bovine bronchial epithelial cells. J Histochem Cytochem. 2007; 55:433–42.
[PubMed: 17242464]
36. Failly M, Saitta A, Muñoz A, et al. DNAI1 mutations explain only 2% of primary ciliary
dykinesia. Respiration. 2008; 76:198–204. [PubMed: 18434704]
37. Guichard C, Harricane MC, Lafitte JJ, et al. Axonemal dynein intermediate-chain gene (DNAI1)
mutations result in situs inversus and primary ciliary dyskinesia (Kartagener syndrome). Am J
Hum Genet. 2001; 68:1030–1035. [PubMed: 11231901]
38. Hornef N, Olbrich H, Horvath J, et al. DNAH5 Mutations are a Common Cause of Primary Ciliary
Dyskinesia with Outer Dynein Arm Defects. Am J Respir Crit Care Med. 2006; 174:120–126.
[PubMed: 16627867]
39. Olbrich H, Haffner K, Kispert A, et al. Mutations in DNAH5 cause primary ciliary dyskinesia and
randomization of left-right asymmetry. Nat Genet. 2002; 30:43–44.
40. Pennarun G, Escudier E, Chapelin C, et al. Loss-of-function mutations in a human gene related to
Chlamydomonas reinhardtii dynein IC78 result in primary ciliary dyskinesia. Am J Hum Genet.
1999; 65:1508–1519. [PubMed: 10577904]
Leigh et al. Page 7













41. Zariwala M, Noone PG, Sannuti A, et al. Germline mutations in an intermediate chain dynein
cause primary ciliary dyskinesia. Am J Respir Cell Mol Biol. 2001; 25:577–583. [PubMed:
11713099]
42. Zariwala MA, Leigh MW, Ceppa F, et al. Mutations of DNAI1 in Primary Ciliary Dyskinesia:
Evidence of founder effect in a common mutation. Am J Respir Crit Care Med. 2006; 174:858–
866. [PubMed: 16858015]
43. Duriez B, Duquesnoy P, Escudier E, et al. A common variant in combination with a nonsense
mutation in a member of the thioredoxin family causes primary ciliary dyskinesia. Proc Natl Acad
Sci USA. 2007; 104:3336–41. [PubMed: 17360648]
44*. Loges NT, Olbrich H, Fenske L, et al. DNAI2 mutations cause primary ciliary dyskinesia with
defects in the outer dynein arm. Am J Hum Genet. 2008; 83:547–58. [PubMed: 18950741] This
study is first to show that mutations in previously identified dynein gene cause PCD with
defective outer dynein arms.
45**. Omran H, Kobayashi D, Olbrich H, et al. Ktu/PF13 is required for cytoplasmic pre- assembly of
axonemal dyneins. Nature. 2008; 456:611–616. [PubMed: 19052621] This study is first to show
that mutations in gene for cytoplasmic proteins alter dynein arm assembly and cause PCD with
defective outer and inner dynein arms.
46*. Marthin JK, Mortensen J, Pressler T, Nielsen KG. Pulmonary radioaerosol mucociliary clearance
in diagnosis of primary ciliary dyskinesia. Chest. 2007; 132:966–76. [PubMed: 17646235] The
study is the first to define patterns of mucociliary clearance pattern in PCD that may be useful for
defining diagnosis.
Leigh et al. Page 8














Schematic showing 9+2 configuration in the cross-section of an axoneme: All of the
axonemal components are labeled. Peripheral microtubules are arranged in 9 doublets (two
microtubule components, A and B, are merged) with dynein arms arising from the A
component. In the center is a pair of microtubules (C1 and C2). Genes mutated in human
PCD are shown and linked with the corresponding axonemal structure that is involved.
* Mutations seen in patient with normal dynein arms
** Encodes cytoplasmic protein that is required for ODA assembly, and mutations seen in
patients with defects involving both outer and inner dynein arms
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Table 1
DIAGNOSIS OF PRIMARY CILIARY DYSKINESIA
Phenotypic clinical features (at least 3, typically 5 or more)
Neonatal respiratory distress in a term infant
Laterality defect (situs inversus totalis or heterotaxy)
Chronic, year-round, nasal congestion
Chronic, year-round, productive cough
Recurrent lower respiratory tract infections
Bronchiectasis
Chronic otitis media (middle ear effusion > 6 months duration)
Chronic pan-sinusitis
Male infertility due to impaired sperm motility
History of primary ciliary dyskinesia in the immediate family.
Laboratory evidence for definitive PCD diagnosis (at least 1)
Classic PCD ultrastructural ciliary defect
- absence or shortening of outer dynein arms
- absence or shortening of inner dynein arms
- absence of radial spokes
- absence of central pair of microtubules with transposition
Genetic diagnosis based on two disease-causing mutations in:
- DNAH5
- DNAI1
- Other genes pending definition of disease-causing mutations
Laboratory evidence supporting diagnosis of “Probable PCD”
(if accompanied by at least 3 phenotypic clinical features)
Nasal nitric oxide levels in very low range (<100 nL/min)*
Laboratory evidence supporting diagnosis of “Possible PCD”
(if accompanied by at least 3 phenotypic clinical features)
Ultrastructural ciliary defects that may overlap with secondary ciliary dyskinesia
- absence of central pair of microtubules (but no transposition)
- absence of cilia on multiple biopsies (ciliary aplasia)
- ciliary disorientation
PCD genetic testing identifying only one disease-causing mutation
Altered ciliary motility on high-speed videomicroscopy **
Altered mucociliary clearance **
*
Availability limited to research sites in United States
**
Specialized diagnostic centers are developing criteria to define specific characteristics that may be consistent with “Probable PCD”.
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